AR064659A1 - Nanoemulsion - Google Patents

Nanoemulsion

Info

Publication number
AR064659A1
AR064659A1 ARP070105827A ARP070105827A AR064659A1 AR 064659 A1 AR064659 A1 AR 064659A1 AR P070105827 A ARP070105827 A AR P070105827A AR P070105827 A ARP070105827 A AR P070105827A AR 064659 A1 AR064659 A1 AR 064659A1
Authority
AR
Argentina
Prior art keywords
nanoemulsion
alcohol
composition
surfactant
diseases
Prior art date
Application number
ARP070105827A
Other languages
English (en)
Inventor
Roca Montserrat Foguet
Original Assignee
Biofrontera Biosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38042639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064659(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biofrontera Biosciences Gmbh filed Critical Biofrontera Biosciences Gmbh
Publication of AR064659A1 publication Critical patent/AR064659A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)

Abstract

Nanoemulsion que comprende por lo menos un componente acuoso y un vehículo, en donde el vehículo comprende por lo menos un componente lipofilo, por lo menos un tensioactivo y por lo menos un alcohol. Composicion que comprende dicha nanoemulsion y un agente activo. En particular, la composicion está presente como un gel y el agente activo es ácido 5-aminolevulínico, un derivado, precursor y/o metabolito del mismo. Preparacion de dicha nanoemulsion y/o composicion y a su uso para el tratamiento de enfermedades dermatologicas, enfermedades asociadas con virus, así como también enfermedades asociadas con proliferacion celular, en particular, enfermedades tumorales y/o psoriasis. Uso de dicha nanoemulsion en cosméticos. Reivindicacion 5: La nanoemulsion de acuerdo con una cualquiera de las reivindicaciones precedentes, caracterizada porque el por lo menos un alcohol es alcohol isopropílico y/o alcohol 1-propílico. Reivindicacion 6: La nanoemulsion de acuerdo con una cualquiera de las reivindicaciones precedentes, caracterizada porque el por lo menos un componente lipofilo consiste en triglicéridos y/o una mezcla de los mismos. Reivindicacion 7: La nanoemulsion de acuerdo con una cualquiera de las reivindicaciones precedentes, caracterizada porque el por lo menos un tensioactivo es lecitina y/o un tensioactivo tipo polioxietileno.
ARP070105827A 2006-12-22 2007-12-21 Nanoemulsion AR064659A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06026698A EP1938801A1 (en) 2006-12-22 2006-12-22 Nanoemulsion

Publications (1)

Publication Number Publication Date
AR064659A1 true AR064659A1 (es) 2009-04-15

Family

ID=38042639

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105827A AR064659A1 (es) 2006-12-22 2007-12-21 Nanoemulsion

Country Status (18)

Country Link
US (2) US11540981B2 (es)
EP (2) EP1938801A1 (es)
JP (1) JP5558827B2 (es)
CN (1) CN101588792B (es)
AR (1) AR064659A1 (es)
AU (1) AU2007338323B2 (es)
BR (1) BRPI0720853A2 (es)
CA (1) CA2670715C (es)
CL (1) CL2007003730A1 (es)
ES (1) ES2602107T3 (es)
IL (1) IL198934A (es)
MX (1) MX2009006088A (es)
NZ (1) NZ577061A (es)
RU (1) RU2491917C2 (es)
UA (1) UA101471C2 (es)
UY (1) UY30833A1 (es)
WO (1) WO2008077641A1 (es)
ZA (1) ZA200903468B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
WO2008140594A2 (en) 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
CA2671447A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
JP2010143848A (ja) * 2008-12-18 2010-07-01 Kao Corp 化粧料
CN101874795A (zh) * 2009-04-28 2010-11-03 上海复旦张江生物医药股份有限公司 5-氨基酮戊酸在制备治疗hpv病毒感染的药物的用途
JP2013502436A (ja) 2009-08-21 2013-01-24 ターゲッティド デリバリー テクノロジーズ リミテッド 小胞状の製剤
US20110200644A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Ester Emulsions
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
WO2011103514A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha triglyceride emulsions
DE202010004750U1 (de) * 2010-04-09 2011-10-11 Biofrontera Bioscience Gmbh Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut
CN103200932A (zh) * 2010-06-23 2013-07-10 布莱特赛德创新有限公司 卵磷脂载体囊泡及其制备方法
BRPI1002486B1 (pt) 2010-07-22 2017-07-18 Evidence Soluções Farmacêuticas Ltda Epp Stabilized topical composition and process of obtaining composition stable topic
JP2012051823A (ja) * 2010-08-31 2012-03-15 Fujifilm Corp 難容性薬物含有水中油型乳化組成物及びその製造方法
KR101448020B1 (ko) * 2010-09-14 2014-10-07 학교법인 도쿄농업대학 암 온열 요법의 작용 증강제
US9789123B2 (en) * 2010-10-21 2017-10-17 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis
MX2013004296A (es) * 2010-10-21 2013-09-26 Cadila Healthcare Ltd Composiciones farmaceuticas topicas que contienen gotas de tamaño nanometrico para el tratamiento de soriasis.
AU2011340797B2 (en) * 2010-12-10 2017-08-10 Ns Technologies Pty Ltd Methods for forming miniemulsions and use thereof for delivering bioactive agents
EP2657346B1 (en) 2010-12-24 2017-08-23 ARKRAY, Inc. Method for detecting cancer cell
DE102010056192A1 (de) 2010-12-28 2012-06-28 Gabriele Blume Kolloidales Trägersystem mit penetrierenden Eigenschaften zum Einschließen lipophiler Wirkstoffe und Öle für die topische Anwendung
KR20190014125A (ko) * 2011-01-24 2019-02-11 안테리오스, 인코퍼레이티드 나노입자 조성물, 이의 제형, 및 그의 용도
FR2977801B1 (fr) * 2011-07-11 2013-08-16 Fabre Pierre Dermo Cosmetique Dispositif et procede pour la sterilisation a ultra-haute temperature d'une emulsion, notamment dermo-cosmetique, instable a la temperature de sterilisation
CN102600178A (zh) * 2012-03-08 2012-07-25 西北农林科技大学 一种复方盐酸布替萘芬纳米乳及其制备方法
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
RU2678433C2 (ru) 2012-05-10 2019-01-29 Пейнреформ Лтд. Депо-составы гидрофобного активного ингредиента и способы их получения
GB201208409D0 (en) * 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
JP6112498B2 (ja) * 2012-07-20 2017-04-12 株式会社 Ｍ Ｌａｂｓ 防腐剤・界面活性剤フリーの化粧品原料液、化粧品及び化粧品原料液の調製法
US10137085B2 (en) 2014-03-19 2018-11-27 Nano And Advanced Materials Institute Limited Nanoemulsion for transdermal delivery and method of making the same
US11458096B2 (en) 2014-04-09 2022-10-04 Pulse Pharmaceuticals Pvt. Ltd. Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base
WO2016128858A1 (en) * 2015-02-11 2016-08-18 Towhidi Armin Extender for cryopreservation of bovine sperm
WO2016182926A1 (en) * 2015-05-08 2016-11-17 Affinsci Inc. Preparation of nanoemulsions
JO3680B1 (ar) 2015-05-21 2020-08-27 Dermavant Sciences GmbH تركيبات صيدلانية موضعية
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
WO2017001617A1 (en) 2015-06-30 2017-01-05 Sequessome Technology Holdings Limited Blended formulations
EP3362145B1 (en) 2015-10-15 2021-01-06 DUSA Pharmaceuticals, Inc. Adjustable illuminator for photodynamic therapy and diagnosis
US10603508B2 (en) 2015-10-15 2020-03-31 Dusa Pharmaceuticals, Inc. Adjustable illuminators and methods for photodynamic therapy and diagnosis
GB201522398D0 (en) * 2015-12-18 2016-02-03 Photocure As Device for photodynamic therapy
CN105997875B (zh) * 2016-07-19 2019-05-21 重庆医科大学 一种明显提高难溶性药物生物利用度的油包水型纳米乳及其制备方法
GB2546128A (en) * 2016-09-28 2017-07-12 Photocure Asa Pharamaceutical compositions comprising hexaminolevulinic acid and methods of using the same
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US20200261580A1 (en) * 2017-07-17 2020-08-20 Andrea Willey Photodynamic Therapy Method for Skin Disorders
CN107233303A (zh) * 2017-08-07 2017-10-10 苏州纳美特生物科技有限公司 一种氨基酮戊酸冷霜及其制备方法和应用
TWI719263B (zh) * 2017-10-27 2021-02-21 財團法人國家衛生研究院 用於鼻黏膜之奈米級乳液免疫載劑及其製備方法
US10959975B1 (en) * 2017-11-02 2021-03-30 The Tetra Corporation Antifungal composition, method of making composition, and method of using composition
US10357567B1 (en) * 2018-01-12 2019-07-23 Dusa Pharmaceuticals, Inc. Methods for photodynamic therapy
AU2019266360A1 (en) * 2018-05-11 2021-01-07 Formulytica Pty Ltd Sub-micron emulsions
EP3583954A1 (en) * 2018-06-19 2019-12-25 neubourg skin care GmbH Nanodispersions of birch bark extract, electrospun fibers containing such nanodispersions and their use for the treatment of wounds
US11642411B2 (en) 2018-08-23 2023-05-09 Biofrontera Bioscience Gmbh Photodynamic therapy comprising two light exposures at different wavelengths
AU2019332696A1 (en) * 2018-08-31 2021-03-18 Kemin Industries, Inc. Technology for water dispersible phospholipids and lysophospholipids
WO2020135600A1 (zh) * 2018-12-28 2020-07-02 南京善思生物科技有限公司 纳米农药制剂及其制备方法
CN110169990A (zh) * 2019-06-19 2019-08-27 苏普丘昆基蒂 牛至油治疗猪腹泻自乳化配方产品及制造工艺
CN114081851A (zh) * 2021-11-01 2022-02-25 苏州纳美特生物科技有限公司 保湿喷雾
WO2024209065A1 (en) * 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Pressurized nanoemulsion
WO2024208434A1 (en) * 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Pressurized nanoemulsion
WO2024209064A1 (en) * 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Nanoemulsion without propylene glycol
WO2024208433A1 (en) * 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Nanoemulsion without propylene glycol

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
NZ260307A (en) 1993-04-14 1995-03-28 Colgate Palmolive Co Microemulsion cleaning solution comprising an anionic organic surfactant and a cosurfactant
EP0704209A1 (en) 1994-09-20 1996-04-03 JOHNSON & JOHNSON MEDICAL, INC. Transdermally active pharmaceutical composition containing 5-aminolaevulinic acid
US5780010A (en) 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
SE9503143D0 (sv) 1995-09-12 1995-09-12 Astra Ab New preparation
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US5895786A (en) 1996-05-08 1999-04-20 New York Blood Center, Inc. Method for treating viral infections
ATE229282T1 (de) 1996-09-16 2002-12-15 Nestle Sa Essbare mikroemulsion zum beschichten von nahrungsmitteln, und verwendung zum bräunen und knusprig machen durch mikrowellen
PT842606E (pt) 1996-11-13 2000-08-31 Manuel Gomes Moniz Pereira Microemulsoes de desinfeccao
TWI241915B (en) * 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
US6620437B2 (en) * 1998-07-30 2003-09-16 Colgate-Palmolive Co. Water-in-oil microemulsion for providing cosmetic attributes to fabric softening base composition
DE19852245A1 (de) * 1998-11-12 2000-05-18 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Nanoemulsion
FR2787728B1 (fr) * 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2787703B1 (fr) 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788449B1 (fr) * 1999-01-14 2001-02-16 Oreal Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2795960B1 (fr) * 1999-07-05 2001-10-19 Sanofi Elf Microemulsions stables pour l'administration d'acides gras a l'homme ou a l'animal, et utilisation de ces microemulsions
US7919113B2 (en) * 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
DE10003620A1 (de) * 2000-01-28 2001-08-02 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Formulierung in nichtwässrigen Lösungsmitteln
US20020155084A1 (en) * 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
US6823387B1 (en) * 2000-06-23 2004-11-23 Microsoft Corporation System and method for enhancing a server's ability to withstand a “SYN flood” denial of service attack
EP2269645A3 (en) 2000-08-16 2011-01-12 The General Hospital Corporation doing business as Massachusetts General Hospital Topical aminolevulinic acid-photodynamic therapy for acne vulgaris
JP2002302414A (ja) 2000-12-26 2002-10-18 Kokuriyuudou:Kk スフィンゴ脂質構造物質含有乳化組成物及びその製造方法
AU2002367976B2 (en) * 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
US20030148927A1 (en) * 2001-10-05 2003-08-07 Procyte Corporation Stable solutions of peptide copper complexes and cosmetic and pharmaceutical formulations produced therefrom
CA2473924A1 (en) 2002-01-23 2003-07-31 Light Sciences Corporation Systems and methods for photodynamic therapy
MXPA05004278A (es) * 2002-10-25 2005-10-05 Foamix Ltd Espuma cosmetica y farmaceutica.
ES2286543T3 (es) * 2003-04-17 2007-12-01 Affectis Pharmaceuticals Ag Medios y metodos para diagnosticar y tratar transtornos afectivos.
AU2004273779B2 (en) * 2003-06-04 2009-10-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
EP1598060A1 (en) * 2004-05-18 2005-11-23 Nestec S.A. Oil-in-water emulsion for delivery
FR2872038A1 (fr) * 2004-06-23 2005-12-30 Rhodia Chimie Sa Composition cosmetique comprenant un polyorganosiloxane et ses utilisations
TWI365075B (en) * 2004-09-22 2012-06-01 Kao Corp Microemulsion
ATE412400T1 (de) * 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
JP4444149B2 (ja) 2005-03-30 2010-03-31 株式会社ナリス化粧品 超微細エマルジョンで構成される皮膚外用剤
US20090130227A1 (en) 2005-04-28 2009-05-21 Yoshiyasu Ito External preparation for skin
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion

Also Published As

Publication number Publication date
CN101588792A (zh) 2009-11-25
ZA200903468B (en) 2010-02-24
US20090324727A1 (en) 2009-12-31
NZ577061A (en) 2012-01-12
AU2007338323B2 (en) 2013-07-11
RU2009128179A (ru) 2011-01-27
EP1938801A1 (en) 2008-07-02
CN101588792B (zh) 2012-03-21
WO2008077641A1 (en) 2008-07-03
US20230201087A1 (en) 2023-06-29
EP2120872A1 (en) 2009-11-25
CA2670715C (en) 2015-11-24
EP2120872B1 (en) 2016-09-21
RU2491917C2 (ru) 2013-09-10
BRPI0720853A2 (pt) 2014-03-25
UY30833A1 (es) 2008-07-31
US11540981B2 (en) 2023-01-03
AU2007338323A1 (en) 2008-07-03
CA2670715A1 (en) 2008-07-03
JP5558827B2 (ja) 2014-07-23
UA101471C2 (en) 2013-04-10
CL2007003730A1 (es) 2009-01-23
IL198934A (en) 2016-04-21
IL198934A0 (en) 2010-02-17
JP2010513363A (ja) 2010-04-30
MX2009006088A (es) 2009-08-28
ES2602107T3 (es) 2017-02-17

Similar Documents

Publication Publication Date Title
AR064659A1 (es) Nanoemulsion
CR9348A (es) Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer
BRPI0915439B8 (pt) composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição
CL2013002550A1 (es) Una formulacion farmaceutica inyectable subcutanea liquida estable altamente concentrada de un anticuerpo anti-her2 farmaceuticamente activo que consiste esencialmente de trastuzumab; his/hci un agente estabilizador y un surfactante no ionico; kit y su uso para tratar enfermedades tales como cancer (divisional de solicitud n°0269-2012).
CO6720961A2 (es) Imidazopiridazinas sustituidas
DOP2011000188A (es) Compuestos de tiazolopiridinas moduladores de sirtuina
BR112014017650A2 (pt) composições e uso de ésteres de forbol
PE20080331A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
BRPI0925036B8 (pt) uso de trans-t-butil ciclo-hexanol, composição cosmética, medicamento, seus usos e processos para tratar irritação na pele
BRPI0512237A (pt) cis-imidazolinas
AR062059A1 (es) Espuma farmaceutica con acido graso
NO20083780L (no) Topisk sammensetning omfattende en antibakteriell substans
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
BR112012007820A2 (pt) derivados contendo antraquinona como produtos agrícolas bioquímicos
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BR112013003658A2 (pt) compostos antivirais contendo azida
BR112015021124A2 (pt) solução para acne
DOP2015000128A (es) Dispersión sólida con solubilidad mejorada que comprende un derivado de tetrazol como ingrediente activo
BRPI0811949B8 (pt) novo princípio ativo em cicatrização e seu uso
AR061269A1 (es) Composicion y metodo de revascularizacion para el tratamiento de enfermedades isquemicas usando eritropoyetina
CL2008001282A1 (es) Composicion farmaceutica con actividad antimicrobiana que comprende un aminoacidos n halogenado y un agente antiinflamatorio; uso para prevenir o tratar una infeccion de tejidos, donde dicho tejido es ocular, nasal, seno nasal o dermico o una infeccion respiratoria.
BR112014005966A2 (pt) composições para o tratamento de úlceras periféricas de várias origens
AR051429A1 (es) Composicion farmaceutica ozonizada y metodos para obtenerla
MX2017010806A (es) Formulacion de acido 18-beta-glicirretinico en combinacion con revesterol y metformina, usos y metodo de fabricacion.
AR054361A1 (es) Uso de acido adamantil metoxidifenil propenoico para el tratamiento de enfermedades dermatologicas

Legal Events

Date Code Title Description
FC Refusal